About
Immune therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
111
By Phase
PHASE1: 3
By Status
RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07024641Lead Sponsor
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
PHASE1Recruiting
48 participants
Started: Nov 13, 2024 · Completed: Sep 30, 2027
NCT06258304Lead Sponsor
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
PHASE1Recruiting
60 participants
Started: May 8, 2024 · Completed: Nov 30, 2027
NCT04883138Lead Sponsor
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
PHASE1Terminated
3 participants
Started: May 24, 2021 · Completed: Jan 11, 2022
Locations (1)
Headquarters
San Carlos, CA, United States
Map
Loading map...